Search Result

Results for "

influenza A strains

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Influenza Virus (34) Akt (1) Antibiotic (1) Apoptosis (1) Bacterial (1) Complement System (1) DNA/RNA Synthesis (3) Drug Derivative (1) EGFR (1) Endogenous Metabolite (3) Endonuclease (1) Fc Receptor (FcR) (1) Fungal (1) Furin (1) Glutathione S-transferase (1) HSV (1) IFNAR (1) Interleukin Related (1) Nucleoside Antimetabolite/Analog (1) p38 MAPK (1) Parasite (1) Reactive Oxygen Species (ROS) (1) SARS-CoV (1) STAT (1)
By Research Areas:	Cancer (1) Infection (38) Neurological Disease (1)

By Targets:

Influenza Virus (34)

Akt (1)

Antibiotic (1)

Apoptosis (1)

Bacterial (1)

Complement System (1)

DNA/RNA Synthesis (3)

Drug Derivative (1)

EGFR (1)

Endogenous Metabolite (3)

Endonuclease (1)

Fc Receptor (FcR) (1)

Fungal (1)

Furin (1)

Glutathione S-transferase (1)

HSV (1)

IFNAR (1)

Interleukin Related (1)

Nucleoside Antimetabolite/Analog (1)

p38 MAPK (1)

Parasite (1)

Reactive Oxygen Species (ROS) (1)

SARS-CoV (1)

STAT (1)

By Research Areas:

Cancer (1)

Infection (38)

Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: Influenza Virus

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N7922

Urolithin M5 1 Publications Verification Decarboxyellagic acid	Influenza Virus p38 MAPK EGFR Akt Reactive Oxygen Species (ROS) Apoptosis	Infection Neurological Disease
Urolithin M5 (Decarboxyellagic acid) is an orally active influenza virus neuraminidase inhibitor and neuroprotective agent, with IC₅₀ values of 174.8 μM (HK68), 191.5 μM (pdm09), 243.2 μM (WSN) and 257.1 μM (PR8) against four influenza virus neuraminidases, respectively. Urolithin M5 inhibits viral neuraminidase activity, thereby blocking influenza virus replication (including oseltamivir (HY-13317)-resistant strains), protecting infected mammals from death and improving pulmonary edema. Urolithin M5 forms a hydrogen-bond stabilized complex with IGF1R, and binds to MAPK14, AKT1, NFKB1 and EGFR. Urolithin M5 reduces reactive oxygen species production, inhibits neuronal apoptosis, restores mitochondrial transmembrane potential, and promotes neurite outgrowth of damaged neuronal cells. Urolithin M5 can be used in research related to influenza virus infection and Alzheimer's disease .

HY-W011518

2′-Deoxy-2′-fluoroguanosine 1 Publications Verification	Nucleoside Antimetabolite/Analog Influenza Virus	Infection
2′-Deoxy-2′-fluoroguanosine is a nucleoside analog and potent influenza virus inhibitor with an EC₉₀ value of <0.35 μM against influenza A and B viruses. 2′-Deoxy-2′-fluoroguanosine inhibits influenza virus replication in the upper respiratory tract, thereby ameliorating fever and nasal inflammation .

HY-14837

Amizon Enisamium iodide	Influenza Virus SARS-CoV	Infection
Amizon is an orally effective antiviral and anti-inflammatory agent. Amizon inhibits influenza virus replication and restricts viral RNA synthesis. Amizon reduces the mRNA expression of COX-1, COX-2, NF-κB, TGF1β, IL-1 and IL-6, and stimulates the secretion and mRNA expression of IL-10. Amizon inhibits the oxidative activity of macrophages and possesses antioxidant and free radical-scavenging activities. Amizon is applicable to research related to influenza and acute respiratory viral infections .

HY-164390

6′SLN Neu5Acα2-6Galβ1-4GlcNAc	Endogenous Metabolite	Infection Cancer
6′SLN is a cancer-related extracellular vesicle (EVs) surface glycan that serves as a key form of protein glycosylation in EVs. 6′SLN is also a sialic acid derivative that can interact with hemagglutinins (HAs) from human and avian influenza virus strains, making it useful for research into anti-influenza drugs .

HY-121473

Aklavin	Antibiotic Bacterial Fungal Parasite	Infection
Aklavin is a structural analog of Aclacinomycin A (HY-N2306) produced by Streptomyces strain A 1165. Aklavin possesses Z-DNA-inducing and stabilizing activities, along with antibiotic, anti-phage and broad-spectrum antimicrobial activities. Aklavin inhibits the proliferation of various viruses (such as influenza virus and poliovirus) and interferes with their nucleoprotein synthesis, while also exhibiting inhibitory effects on staphylococci, mycobacteria and specific fungi. Aklavin blocks phage-induced bacterial lysis by regulating host-parasite interactions. Aklavin shows specific toxicity to fertilized eggs and mice, and does not alter the splicing of the SMN2 gene .

HY-P1788

Influenza A NP(366-374) Strain A/PR/8/35	Influenza Virus	Infection
Influenza A NP(366-374) Strain A/PR/8/35 is an H2-Db-restricted epitope from Influenza A/PR/8/35 nucleoprotein .

HY-P1837

Influenza HA (518-526)	Influenza Virus HSV	Infection
Influenza HA (518-526) is an H-2d-restricted CTL epitope derived from influenza virus hemagglutinin. Influenza HA (518-526) is highly conserved across various H5N1, some H9N2, and H1N1 strains. Influenza HA (518-526) binds to the mouse MHC class I allele K ^d to form a complex, which is then recognized by specific CD8 ⁺ T cells. Influenza HA (518-526) is an immunodominant epitope in influenza-infected BALB/c mice, and it stimulates CD8 ⁺ T cells to secrete IFN-γ to induce a robust immune response. Currently, Influenza HA (518-526) is widely used in research related to respiratory syncytial virus (RSV), influenza virus, and H5N1 influenza .

HY-130178

CL-385319	Endogenous Metabolite	Infection
CL-385319 is an N-substituted piperidine compound with inhibitory activity against H5N1 avian influenza A virus infection. CL-385319 exhibited an IC50 of 27.03±2.54 μM against infection of highly pathogenic H5N1 virus in Madin-Darby canine kidney cells (MDCK). CL-385319 had low cytotoxicity with a CC50 of 1.48 mM and was able to inhibit the entry of pseudoviruses carrying H5N1 strains from different sources, but had no inhibitory effect on the entry of VSV-G pseudotyped particles. Pseudoviruses with the M24A mutation in HA1 or the F110S mutation in HA2 were resistant to CL-385319, indicating that these two residues in the cavity region may be critical for the binding of CL-385319 .

HY-P1783A

M2e, human TFA 1 Publications Verification	Influenza Virus	Infection
M2e, human TFA, consisting of the 23 extracellular residues of M2 (the third integral membrane protein of influenza A), has been remarkably conserved in all human influenza A. M2e, human TFA is a valid and versatile vaccine candidate to protect against any strain of human influenza A .

HY-148309

Anti-Influenza agent 4	Influenza Virus	Infection
Anti-Influenza agent 4 is a potent and selective influenza virus inhibitor with EC₅₀s of 150 nM and 62 nM for strains A/Roma and A/Parma, respectively .

HY-131069A

MBX2329	Influenza Virus	Infection
MBX2329, a potent influenza virus inhibitor, specifically inhibits hemagglutinin (HA)-mediated viral entry with HIV/HA(H5) displaying IC₉₀ of 8.6 μM. MBX2329 inhibits a wide spectrum of influenza A viruses, which includes the 2009 pandemic influenza virus A/H1N1/2009, highly pathogenic avian influenza (HPAI) virus A/H5N1, and oseltamivir-resistant A/H1N1 strains .

HY-P991054

CR-8020	Influenza Virus	Infection
CR-8020 is a human IgG1 antibody that targets influenza A virus H3N2. CR-8020 binds to hemagglutinin (HA) of H3N2 strains with IC₅₀s of 3.36 nM and 0.06 nM for A/Brisbane/10/2007 and A/Wyoming/3/2003, respectively. The isotype control for CR-8020 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-134931

M090	Influenza Virus	Infection
M090 is the inhibitor for the hemagglutinin of influenza A Virus, that inhibits various influenza strains with EC₅₀ of micromolar levels .

HY-156288

Anti-Influenza agent 5	Influenza Virus	Infection
Anti-Influenza agent 5 (Compound IIB-2), chalcone-like derivative, is an influenza nuclear export inhibitor. Anti-Influenza agent 5 has inhibitory effects on oseltamivir-resistant strains. Anti-Influenza agent 5 can impede virus proliferation by blocking the export of influenza virus nucleoprotein .

HY-P1783

M2e, human	Influenza Virus	Infection
M2e, human, consisting of the 23 extracellular residues of M2 (the third integral membrane protein of influenza A), has been remarkably conserved in all human influenza A, which is a valid and versatile vaccine candidate to protect against any strain of human influenza A .

HY-155476

Influenza virus-IN-8	Influenza Virus	Infection
Influenza virus-IN-8 (compound A4) is an inhibitor of influenza virus (Influenza Virus) that induces viral nucleoprotein (NP) aggregation and prevents its nuclear accumulation. Influenza virus-IN-8 has broad-spectrum anti-influenza activity and can inhibit the replication and transcription of influenza A virus. Influenza virus-IN-8 also inhibits Oseltamivir (HY-13317)-resistant H1N1/pdm09 strains .

HY-162680

OSC-GCDI(P)	Influenza Virus	Infection
OSC-GCDI(P) is a broad-spectrum orally active anti-influenza virus agent that exhibits significant inhibitory effects against both wild-type and Oseltamivir (HY-13317) resistant (H275Y) influenza virus strains in mouse infection models. OSC-GCDI(P) is capable of preventing not only wild-type influenza viruses but also OS-resistant variants with NA(H275Y) .

HY-162801

Neuraminidase-IN-21	Influenza Virus	Infection
Neuraminidase-IN-21 (Compound 6d) is an influenza H1N1 virus Neuraminidase inhibitor, with IC₅₀s of 0.30 µM for Neuraminidase, and 30.01 µM for H1N1 strain of influenza. Neuraminidase-IN-21 formsg three hydrogen bonds with Arg292, Arg371, and Tyr406 of Neuraminidase .

HY-147881

Anti-Influenza agent 3	Influenza Virus	Infection
Anti-Influenza agent 3 (compound 11h) is a potent *anti-influenza* agent with EC₅₀ values of 3.29, 2.45 µM for A/HK/68 (H3N2, M2-WT), A/WSN/33 (H1N1, M2-S31N) strain, respectively. Anti-Influenza agent 3 shows low cytotoxicity for MDCK epithelial cells. Anti-Influenza agent 3 inhibits the M2 WT and S31N ion channel conductivity .

HY-143781

Cap-dependent endonuclease-IN-26	Influenza Virus	Infection
Cap-dependent endonuclease-IN-26 is a cap-dependent endonuclease (CEN) inhibitor with an IC₅₀ of 286 nM. Cap-dependent endonuclease-IN-26 shows antiviral activity against many influenza A and B strains .

HY-157249

Antiviral agent 43	Influenza Virus	Infection
Antiviral agent 43 (compound 16) is a potent and orally active influenza A viruses entry inhibitor. Antiviral agent 43 inhibits replications of influenza A strains VH04-H5N1 and PR8-H1N1 with EC₅₀s of 240 nM and 72 nM, respectively .

HY-N2264

Wulignan A1	Influenza Virus	Infection
Wulignan A1 is isolated from the stems of Schisandra henryi. Wulignan A1 exhibits anti-influenza virus H1N1 and H1N1-TR (a Tamiflu agent resistant virus strain) activities .

HY-174431

PAN endonuclease-IN-3	Endonuclease Influenza Virus	Infection
PAN endonuclease-IN-3 is a potent PAN endonuclease inhibitor that against influenza virus polymerase complexes with an IC₅₀ of 17.4 nM. PAN endonuclease-IN-3 demonstrates potent inhibitory activities against PAN endonuclease. PAN endonuclease-IN-3 demonstrates robust antiviral activities against multiple current and different influenza virus strains while showing minimal cytotoxicity in MDCK cells. PAN endonuclease-IN-3 significantly suppresses viral replication in an A/WSN/33 infected mouse model.

HY-151967

Anti-IAV agent 1	Influenza Virus	Infection
Anti-IAV agent 1 (Compound (R)-1a) is an orally active anti-influenza A virus (IAV) agent with IC₅₀s of 0.03 and 0.06 μM against IAV H1N1 and Oseltamivir-resistant IAV H1N1 strains, respectively .

HY-144668

RdRP-IN-4	DNA/RNA Synthesis Influenza Virus	Infection
RdRP-IN-4 (compound 11q), an aryl benzoyl hydrazide analog, is an orally active influenza A virus RNA-dependent RNA polymerase (RdRp) inhibitor by interacting with the PB1 subunit. RdRP-IN-4 exhibits potent inhibitory activity against the avian H5N1 flu strain with an EC50 of 18 nM in MDCK cells. RdRP-IN-4 displays excellent potency against the the H1N1 (A/PR/8/34) Flu A strain and Flu B strain (B/Lee/1940) with EC50 values of 53 nM and 20 nM, respectively. RdRP-IN-4 significantly inhibits the expression level of viral nucleoprotein (NP) in a dose-dependent manner. RdRP-IN-4 exhibits significant antiviral activity in infected mice .

HY-124305

ML395	Endogenous Metabolite	Infection
ML395 is a potent and selective allosteric inhibitor of phospholipase D2 with antiviral activity. The cellular PLD1 IC50 value of ML395 exceeds 30,000 nM, while its cellular PLD2 IC50 value is 360 nM. ML395 shows excellent pharmacokinetic characteristics in vitro and physiochemical properties superior to other reported phospholipase inhibitors. ML395 shows interesting antiviral activity in cell-based assays against multiple influenza virus strains (H1, H3, H5, and H7) .

HY-175808

VF-57a	Influenza Virus	Infection
VF-57a (Compound 23) is an Influenza A virus (IAV) fusion inhibitor. VF-57 has potent antiviral activities against authentic A/H1N1 virus with EC₅₀s of 0.92 and 0.31 μM for the A/H1N1 PR8 and A/H1N1 Virg09 strains, respectively. VF-57 significantly inhibits HA-mediated cell entry of A/H1N1- and A/H5N1-pseudoviruses, prevents the HA refolding at pH 5.2. VF-57a can be used for IAV infections research .

HY-180525

PB2-IN-2	Influenza Virus	Infection
PB2-IN-2 is an orally active PB2 inhibitor with RNA-dependent RNA Polymerase (RNP) IC₅₀ = 0.2 nM, LRA (Ligand Receptor Assay) EC₅₀ = 0.8 nM, Cytopathic Effect (CPE) EC₅₀ = 0.1 nM. PB2-IN-2 exhibits broad-spectrum, nanomolar antiviral potency against a panel of influenza A strains (including H1N1pdm09, Lyon/1337/2007/H1N1, Tex12-Like/H3N2, PR/8/34/H1N1, WSN/1933/H1N1, rPR8(H1N1)/H7N9 with EC₅₀ = 1.5, 3.6, 3.7, 13.8, 2.9 and 9.8 nM and all the CC₅₀ values > 2 μM. PB2-IN-2 possesses an excellent pharmacokinetic profile and metabolic stability. PB2-IN-2 can be used for anti-influenza research .

HY-178455

Influenza virus-IN-10	Influenza Virus	Infection
Influenza virus-IN-10 is a dual-target antiviral agents for influenza that targets both PA_C (K_D = 8.9 μM) and NP (K_D = 52.5 μM) simultaneously. Influenza virus-IN-10 exhibits an EC₅₀ values of 1.64 μM) against influenza A virus (H1N1, A/WSN/33) and broad-spectrum activity against other influenza strains, including influenza B virus and multiple subtypes of influenza A .

HY-124184

D715-2441	DNA/RNA Synthesis Influenza Virus	Infection
D715-2441 is an influenza virus RNA polymerase inhibitor (IC₅₀=1.7-4.4 μM). D715-2441 exhibits broad-spectrum antiviral activity against multiple influenza A strains. D715-2441 is promising for research of seasonal influenza and influenza viruses .

HY-P992482

VIR-2482	Drug Derivative Influenza Virus Fc Receptor (FcR) Complement System	Infection
VIR-2482 is a monoclonal antibody targeting influenza A hemagglutinin (HA). VIR-2482 is generated by introducing LS mutations (M428L/N434S) into the Fc region of MEDI8852 (HY-P991446). VIR-2482 binds to the conserved HA stem epitope across all 18 influenza A HA subtypes, neutralizes a broad spectrum of H1N1 and H3N2 strains, binds to FcγRIIIa, FcγRIIa and C1q, and induces antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. VIR-2482 reduces morbidity and mortality caused by seasonal influenza A strains and provides prophylactic protection in mice. VIR-2482 can be used in research related to influenza A disease .

HY-181915

PB2-IN-3	Influenza Virus	Infection
PB2-IN-3 (Compound 11) is a PB2 inhibitor. PB2-IN-3 exhibits antiviral activity against Influenza A H1N1 and H3N2 strains. PB2-IN-3 can be used in studies related to influenza A virus infection .

HY-180269

Anti-Influenza agent 10	Influenza Virus DNA/RNA Synthesis	Infection
Anti-Influenza agent 10 (Compound 41) is an influenza A virus RNA-dependent RNA polymerase (RdRp) inhibitor. Anti-Influenza agent 10 exhibits potent antiviral activity against A/PR/8/34(H1N1) with an IC₅₀ of 0.29μM and a K_D of 4.11 μM. Anti-Influenza agent 10 can inhibit the assembly of the viral RdRp complex by disrupting the protein interaction between PA and PB1 subunits, thereby blocking the transcription and replication of the viral genome. Anti-Influenza agent 10 shows significant broad-spectrum effects on multiple influenza virus strains, such as H3N2, H3N8 and H9N2 with IC₅₀ values of 3.96, 1.91 and 1.45 μM. Anti-Influenza agent 10 can be used for the research of influenza A Virus Infection .

HY-181785

Influenza A virus-IN-18	Influenza Virus	Infection
Influenza A virus-IN-18 (Compound C2e) is an orally active inhibitor of Influenza A virus (IC₅₀: 2.5 μM against PR8/H1N1; 6.42 μM against H3N2). Influenza A virus-IN-18 binds directly to the H1N1/PR8 HA protein with high affinity, with a K_D of 0.25 μM. Influenza A virus-IN-18 is applicable to research related to Influenza A virus infection .

HY-Z3651

Oseltamivir impurity-1	Influenza Virus	Infection
Oseltamivir impurity-1 (Page 2, Row 4, Column 3), a carboxylic acid derivative, is an impurity of Oseltamivir (HY-13317). Oseltamivir impurity-1 shows antiviral effect on multiple influenza virus strains .

HY-N17963

Cappariloside A	Glutathione S-transferase Influenza Virus Interleukin Related IFNAR STAT	Infection
Cappariloside A is a larvicide that exhibits larvicidal activity against Aedes aegypti larvae and reduces larval glutathione-S-transferase activity. Cappariloside A also possesses antiviral activity, decreases the level of phosphorylated STAT1 in cells, inhibits the replication of influenza viruses H1N1, H3N2, PIV3 and ADV, and downregulates the expression of IL-6, IP-10, MIG, RANTES/CCL-5, IFN-β and IL-29. Cappariloside A suppresses the inflammatory response induced by mouse lung-adapted influenza virus strains. Cappariloside A can be used in studies related to larvicidal applications and influenza virus infection .

HY-182895

Influenza A virus-IN-19	Influenza Virus	Infection
Influenza A virus-IN-19 (Compound (S)-63) is an orally active, selective Influenza A virus inhibitor with an EC₅₀ of 0.44 μM. Influenza A virus-IN-19 exhibits moderate binding affinity to Hemagglutinin, with a K_d of 5.66 μM. Influenza A virus-IN-19 inhibits trypsin-mediated cleavage of HA0, blocks the early viral entry process, and suppresses the replication of Influenza A virus. Influenza A virus-IN-19 improves the survival rate of mice in lethal influenza models. Influenza A virus-IN-19 can be used in studies related to Influenza A virus infection .

HY-180145

Furin-IN-3	Furin Influenza Virus	Infection
Furin-IN-3 (Compound 9) is a potent and selective proprotein convertase furin inhibitor with a K_i of 12.4 nM. Furin-IN-3 shows a K_i of 278 nM for PC7. Furin-IN-3 shows a significant antiviral effect on the Furin-dependent H7N7 influenza A virus strain SC35M. Furin-IN-3 can inhibit the cleavage and activation of the viral hemagglutinin (HA), prevent the fusion of the viral membrane with the host cell membrane, and thereby inhibit viral replication and proliferation. Furin-IN-3 can be used for the research of infection, such as influenza virus infection .

Cat. No.	Product Name

HY-L113

Antiviral Traditional Chinese Medicine Active Compound Library	235 compounds
Increasing research have shown that Traditional Chinese Medicine (TCM) possess antiviral activities against various viral strains, such as herpes simplex virus, influenza virus, hepatitis B and C viruses, and SARS-CoV. To date, dozens of Chinese herbs and hundreds of natural TCM ingredients have been reported to exhibit good antiviral activities. Active components from TCM are one of the important sources for antiviral drugs discovery. MCE designs a unique collection of 235 active compounds of antiviral Chinese Herbal Medicines. MCE Antiviral Traditional Chinese Medicine Active Compound Library is a useful tool for discovery antiviral drugs from TCM.

Antiviral Traditional Chinese Medicine Active Compound Library

235 compounds

Increasing research have shown that Traditional Chinese Medicine (TCM) possess antiviral activities against various viral strains, such as herpes simplex virus, influenza virus, hepatitis B and C viruses, and SARS-CoV. To date, dozens of Chinese herbs and hundreds of natural TCM ingredients have been reported to exhibit good antiviral activities. Active components from TCM are one of the important sources for antiviral drugs discovery.

MCE designs a unique collection of 235 active compounds of antiviral Chinese Herbal Medicines. MCE Antiviral Traditional Chinese Medicine Active Compound Library is a useful tool for discovery antiviral drugs from TCM.

HY-L940

Antiviral Lead-like compound library	5,813 compounds
Owing to the widespread transmission and frequent mutation of viral diseases, as well as the continuous emergence of new viruses and drug-resistant strains, antiviral drug development is facing increasingly stringent requirements. Antiviral compound libraries serve as important tools for drug screening, mechanism research and development, enabling the discovery and investigation of various antiviral drugs. These compounds act through diverse antiviral mechanisms, targeting key steps in viral replication, assembly and invasion. They exert antiviral effects by inhibiting viral nucleic acid synthesis, blocking viral protein processing, and preventing viral binding to host cells. This library covers various types of antiviral compounds, including nucleosides, non-nucleosides, protease inhibitors and integrase inhibitors. It supports research on influenza virus, herpes virus, hepatitis virus, emerging respiratory viruses and other pathogens, and enables high-throughput screening of novel antiviral candidates to rapidly identify potential active compounds against diverse viruses. It also facilitates mechanistic studies to elucidate drug-target interactions and viral resistance mechanisms, and supports the screening of effective compounds against mutant strains for research on viral variation and drug resistance. This antiviral library consists of 6,804 compounds with lead-like physicochemical properties. The core sources of the compounds include analogs of known antiviral molecues with a similarity score ≥ 0.6. MCE has collected more than 1450 antiviral molecules. As a small-molecule collection with both activity potential and structural modifiability, it provides strong support for antiviral drug research and development.

Antiviral Lead-like compound library

5,813 compounds

Owing to the widespread transmission and frequent mutation of viral diseases, as well as the continuous emergence of new viruses and drug-resistant strains, antiviral drug development is facing increasingly stringent requirements. Antiviral compound libraries serve as important tools for drug screening, mechanism research and development, enabling the discovery and investigation of various antiviral drugs.

These compounds act through diverse antiviral mechanisms, targeting key steps in viral replication, assembly and invasion. They exert antiviral effects by inhibiting viral nucleic acid synthesis, blocking viral protein processing, and preventing viral binding to host cells. This library covers various types of antiviral compounds, including nucleosides, non-nucleosides, protease inhibitors and integrase inhibitors. It supports research on influenza virus, herpes virus, hepatitis virus, emerging respiratory viruses and other pathogens, and enables high-throughput screening of novel antiviral candidates to rapidly identify potential active compounds against diverse viruses. It also facilitates mechanistic studies to elucidate drug-target interactions and viral resistance mechanisms, and supports the screening of effective compounds against mutant strains for research on viral variation and drug resistance.

This antiviral library consists of 6,804 compounds with lead-like physicochemical properties. The core sources of the compounds include analogs of known antiviral molecues with a similarity score ≥ 0.6. MCE has collected more than 1450 antiviral molecules. As a small-molecule collection with both activity potential and structural modifiability, it provides strong support for antiviral drug research and development.

Cat. No.	Product Name	Target	Research Area